Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
5.14
+0.06 (1.18%)
At close: May 29, 2026, 4:00 PM EDT
5.15
+0.01 (0.19%)
After-hours: May 29, 2026, 5:57 PM EDT
Lexeo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
59
Market Cap
403.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 654.00K | -1.00M | -60.53% |
| Dec 31, 2021 | 1.66M | 1.14M | 219.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 217.78M |
| Enanta Pharmaceuticals | 69.21M |
| Verastem | 49.59M |
| vTv Therapeutics | 36.84M |
| OmniAb | 28.94M |
| Prelude Therapeutics | 16.72M |
| X4 Pharmaceuticals | 9.01M |
| Artiva Biotherapeutics | 251.00K |
LXEO News
- 12 days ago - Lexeo Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 12 days ago - Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 20 days ago - Lexeo Therapeutics reports Q1 EPS (25c), consensus (30c) - TheFly
- 20 days ago - Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights - GlobeNewsWire
- 20 days ago - Lexeo Therapeutics Quarterly report: Q1 2026 - Filings
- 20 days ago - Lexeo Therapeutics Earnings release: Q1 2026 - Filings
- 20 days ago - Lexeo Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Lexeo Therapeutics Proxy statement: Proxy filing - Filings